Cybin Inc. logo

CYBN Q2 2025 Earnings Results — Cybin Inc.

XASE · Healthcare · Biotechnology

Updated

Price $8.28
Market Cap $195.3M
P/E —
52W Range $5.50 – $9.12

When is CYBN's next earnings date?

Cybin Inc. (CYBN) has not announced its next earnings date yet. Its most recent earnings report was on Thursday, November 13, 2025.

How did CYBN do in its last earnings report?

In its most recent report on Nov 13, 2025 (Q2 2025), Cybin Inc. posted EPS of -$1.39 versus the -$1.09 estimate, a miss of 27.5%. Revenue was $0. The stock's 1-day post-earnings move was -8.0%.

How much does CYBN stock move after earnings?

CYBN beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.4% (up or down) in the day after earnings.

About Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Earnings History

DatePeriodEPS Est.EPS Act.SurpriseRevenueResult1D Δ1W Δ1M Δ
2025-11-13Q2 2025-1.09-1.39-27.52%$0❌ Miss-8.05%-8.20%+3.41%
2025-08-13Q1 2025-0.56-1.10-96.43%$0❌ Miss-0.39%-13.63%-21.23%
2025-02-11Q3 2024-1.57-0.38+75.92%$0✅ Beat-0.32%-0.75%-22.26%
2024-11-13Q2 2024-0.96-2.10-118.75%$0❌ Miss-10.26%-5.98%-14.19%
2024-06-26Q4 2023-1.52-0.38+75.00%$0✅ Beat+0.10%+0.40%+8.18%
2024-02-14Q3 2023-1.52-2.66-75.00%$0❌ Miss-3.44%+6.44%+19.33%
2023-11-14Q2 2023-1.90-1.52+20.00%$0✅ Beat-1.09%+1.54%-9.78%
2023-08-14Q1 2023-2.28-1.90+16.67%$0✅ Beat+3.94%-2.17%+0.89%

Showing last 8 quarters.

Related Companies

Learn More

Explore More

Financial data from licensed market-data providers; risk factors from SEC EDGAR filings. AI-powered analysis. Data last updated .